Table 4. Subgroup analyses of optimal cutoff value in different population sets of SEER cohort.
| Population | No. of patients (%) | 3-year OS (%) | 5-year OS (%) | HR (95% CI) | P value |
|---|---|---|---|---|---|
| Female | 0.037 | ||||
| ELNs >31 | 10 (13.2) | 70.0 | 60.0 | 1 (Ref.) | |
| ELNs ≤31 | 66 (86.2) | 31.8 | 25.7 | 2.778 (1.004–7.741) | |
| Male | 0.035 | ||||
| ELNs >31 | 6 (5.0) | 83.3 | 83.3 | 1 (Ref.) | |
| ELNs ≤31 | 114 (95.0) | 32.5 | 29.7 | 8.667 (1.206–62.708) | |
| Age ≤60 years | 0.161 | ||||
| ELNs >31 | 6 (9.1) | 83.3 | 66.7 | 1 (Ref.) | |
| ELNs ≤31 | 60 (90.9) | 41.7 | 38.1 | 1.845 (0.569–5.983) | |
| Age >60 years | 0.011 | ||||
| ELNs >31 | 10 (7.7) | 70.0 | 70.0 | 1 (Ref.) | |
| ELNs ≤31 | 120 (92.3) | 27.5 | 23.3 | 3.886 (1.229–12.289) | |
| Tumor ≤4 cm | 0.193 | ||||
| ELNs >31 | 3 (7.1) | 66.7 | 66.7 | 1 (Ref.) | |
| ELNs ≤31 | 39 (92.9) | 33.3 | 30.6 | 3.433 (0.466–25.433) | |
| Tumor >4 cm | 0.015 | ||||
| ELNs >31 | 13 (10.8) | 76.9 | 69.2 | 1 (Ref.) | |
| ELNs ≤31 | 107 (89.2) | 32.7 | 30.7 | 3.211 (1.173–8.795) | |
| Upper third | 0.282 | ||||
| ELNs >31 | 2 (8.7) | 50.0 | 50.0 | 1 (Ref.) | |
| ELNs ≤31 | 21 (91.3) | 23.8 | 19.0 | 2.862 (0.378–21.673) | |
| Middle third | 0.580 | ||||
| ELNs >31 | 2 (8.3) | 50.0 | 50.0 | 1 (Ref.) | |
| ELNs ≤31 | 22 (91.7) | 40.9 | 40.9 | 1.723 (0.390–7.618) | |
| Lower third | 0.026 | ||||
| ELNs >31 | 6 (7.0) | 83.3 | 83.3 | 1 (Ref.) | |
| ELNs ≤31 | 80 (93.0) | 32.5 | 27.2 | 3.536 (1.107–12.289) | |
| >2/3 stomach | 0.035 | ||||
| ELNs >31 | 4 (12.9) | 50.0 | 50.0 | 1 (Ref.) | |
| ELNs ≤31 | 27 (87.1) | 25.9 | 18.5 | 4.203 (0.976 –18.097) | |
| Intestinal | 0.015 | ||||
| ELNs >31 | 7 (10.8) | 85.7 | 85.7 | 1 (Ref.) | |
| ELNs ≤31 | 58 (89.2) | 36.2 | 30.8 | 7.768(1.066–56.635) | |
| Diffuse | 0.034 | ||||
| ELNs >31 | 7 (5.6) | 71.4 | 71.4 | 1 (Ref.) | |
| ELNs ≤31 | 118 (94.4) | 28.8 | 25.4 | 4.158 (1.023–16.898) |
No., number; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; ELNs, examined lymph nodes; Ref, reference; TG; total gastrectomy; PG, proximal gastrectomy; DG, distal gastrectomy; SEER, Surveillance, Epidemiology, and End Results.